BioSpace News Archive

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023.

Genetic Technologies Limited – a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce a partnership with the Gold Coast Private Hospital, a member of Healthscope, to establish a Precision Medicine Clinic at the hospital.

Abbott will announce its third-quarter 2023 financial results on Wednesday, Oct. 18, before the market opens.

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomb: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715), “Sun Pharma” is pleased to announce that PRWINLEVI (clascoterone cream 1% w/w) is now available in Canada.

Starpax Biopharma Inc., a biopharmaceutical company developing a groundbreaking cancer treatment platform technology, is pleased to announce the launch of its Regulation A+ capital raise.

HotSpot Therapeutics, Inc. today announced it will present additional preclinical data from the Company’s CBL-B program in a poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 1-5, 2023, in San Diego, CA.

SaNOtize Research and Development Corp. announced that the company has appointed Steven Basta, an experienced biopharma and medical device commercial leader, as its new Chief Executive Officer.

Adicet Bio, Inc. (Nasdaq: ACET) today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023.

Aulos Bioscience today announced that new safety and efficacy data from the Phase 1 dose escalation portion of its Phase 1/2 clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumor cancers will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Tregs, announces that management will present at the LD Micro Investor Conference in Los Angeles, CA on October 3 at 8:00am PT.